Adalank vs Metformin
Emerging vs FDA Approved
monitor Mechanism-based · 46% Both Adalank and Metformin enhance GABAergic activity. Combined CNS depression increases risk of excessive sedation, respiratory depression, and impaired coordination. Do not combine with alcohol.
Molecular Data
Adalank Metformin
Weight 792.93 Da 129.16 Da
Half-life Not established ~5 hours
Chain 7 amino acids —
Type Modified heptapeptide Biguanide (C4H11N5)
Key Benefits
Adalank
01 Potent anxiolytic effects without sedation
02 Enhanced cognitive function
03 Stress resilience
04 Improved mood and emotional stability
05 Neuroprotection via BDNF upregulation
06 No tolerance, dependency, or withdrawal
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Dosing Protocols
Adalank
200-500mcg / Once or twice daily
Anxiety Reduction 200-300mcg 1x daily (morning)
Cognitive Enhancement 200-500mcg 1x daily
Stress Management 200-300mcg 2x daily (morning, afternoon)
Initial Trial 100-200mcg 1x daily
Metformin
500-2000 mg/day / 1-2x daily with meals
Side Effects
Adalank
Parent compound has high safety profile in Russian clinical research
Minimal side effects reported
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Contraindications
Experimental peptide with limited direct human research on N-Acetyl form
Not recommended during pregnancy or breastfeeding
Consult healthcare provider before use with psychiatric medications
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Research Evidence
Adalank Metformin
Status Emerging FDA Approved
References 3 studies 5 studies
Latest — 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.